Company intelligence / Profile preview

JLK

Cheongju, Chungcheongbuk-do, South Korea

Ownership: Private
Development stage: Commercial

Overview

JLK has developed a suite of AI-powered medical imaging solutions for stroke and cancer diagnostics. The company has secured at least six U.S. FDA clearances for its platforms—including tools for large vessel occlusion detection in stroke and prostate cancer MRI analysis—and continues to expand globally with recent launches in the U.S., Japan, Thailand, and Indonesia. Clinical studies have demonstrated competitive performance versus leading global players like RapidAI[3][4][5].

Therapeutic areas: OncologyNeurology
Modalities: AI-based diagnostic software
Industry: Medical Imaging

Partnerships

Collaborations with major university hospitals in Korea for telemedicine services via MEDIHUB TELE[1]

Beyond the preview

Go deeper on JLK.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JLK.

Explore the full profile